Dennis Gage
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1023014776
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,614 of the $5,179 with a category attached, or 89.1%. It is spread thinly across 32 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,391 and has fallen 99.5% since, to $21 in 2021.
Across 269 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$612
- Tosoh Bioscience, Inc.$557
- Boehringer Ingelheim$498
- AbbVie$462
- AstraZeneca$432
- Sanofi-aventis U.S. LLC$414
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,61489%
- Education$90%
- Gifts$55711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $612 |
| Tosoh Bioscience, Inc. | 1 | $557 |
| Boehringer Ingelheim | 36 | $498 |
| AbbVie | 21 | $462 |
| AstraZeneca | 24 | $432 |
| Sanofi-aventis U.S. LLC | 21 | $414 |
| Lilly USA, LLC | 20 | $366 |
| Merck | 17 | $268 |
| Amgen | 11 | $238 |
| Antares Pharma, Inc. | 7 | $144 |
| Shire North American Group Inc | 7 | $131 |
| IBSA Pharma Inc. | 8 | $129 |
| Mannkind Corporation | 7 | $118 |
| Johnson & Johnson | 5 | $113 |
| Aytu Biopharma, Inc. | 7 | $110 |
| Eisai Inc. | 4 | $87 |
| Valeritas, Inc. | 3 | $68 |
| Ipsen Biopharmaceuticals, Inc | 2 | $47 |
| Abbott | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Insulet Corporation | 3 | $40 |
| Companion Medical, Inc. | 2 | $37 |
| Nalpropion Pharmaceuticals LLC | 2 | $36 |
| Radius Health, Inc. | 1 | $32 |
| Medtronic | 1 | $24 |
| Vivus LLC | 2 | $24 |
| Amarin Pharma, Inc. | 1 | $24 |
| OPKO Pharmaceuticals, LLC | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $19 |
| Pfizer | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRL, ST AIA-PACK$557
- TPOAb, AIA-PACK Control Set$557
- TgAb Control Set$557
- LH II, ST AIA-PACK$557
- PTH, AIA-PACK CALIBRATOR SET$557
How this compares
$5,179 in reported general payments places this provider in the 75th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Other endocrinology, diabetes & metabolism in New York
- John BilezikianNew York$809K
- Anastasios ManessisNew York$656K
- Jason BakerNew York$427K
- Brian LevyNew York$417K
- Stuart WeissNew York$275K
- Priya JaisinghaniNew York$239K
- Henry GinsbergNew York$161K
- Recaredo BerbanoNew York$146K
- Beverly TchangNew York$120K
- Shira EytanNew York$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.